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Abstract
Background: Pharmacogenetics is a rapidly growing field that aims to identify the genes that influence drug
response. This science can be used as a powerful tool to tailor drug treatment to the genetic makeup of individuals.
The present study explores the coverage of the topic of pharmacogenetics and its potential benefit in personalised
medicine by the UK newsprint media.
Methods: The LexisNexis database was used to identify and retrieve full text articles from the 10 highest circulation
national daily newspapers and their Sunday equivalents in the UK. Content analysis of newspaper articles which
referenced pharmacogenetic testing was carried out. A second researcher coded a random sample (21%) of
newspaper articles to establish the inter-rater reliability of coding.
Results: Of the 256 articles captured by the search terms, 96 articles (with pharmacogenetics as a major component) met
the study inclusion criteria. The majority of articles over-stated the benefits of pharmacogenetic testing while paying less
attention to the associated risks. Overall beneficial effects were mentioned 5.3 times more frequently than risks (p < 0.001).
The most common illnesses for which pharmacogenetically based personalised medicine was discussed were cancer,
cardiovascular disease and CNS diseases. Only 13% of newspaper articles that cited a specific scientific study mentioned
this link in the article. There was a positive correlation between the size of the article and both the number of benefits
and risks stated (P < 0.01).
Conclusion: More comprehensive coverage of the area of personalised medicine within the print media is needed to
inform public debate on the inclusion of pharmacogentic testing in routine practice.
Keywords: Media, Newspapers, Pharmacogenetics, CNS
Background
The science of pharmacogenetics which aims to define the
genes that affect our response to current drugs is a rapidly
growing field that has gained enormous momentum due to
recent advances in molecular genetics and genome sequen-
cing [1]. It is clear now that much of the individuality in
our response to medications is genetic in nature; under-
standing this individual variability defines the area of
pharmacogenetics and can be a powerful tool to improve
both the efficacy and safety of drug prescribing [2]. More
recently, the term ‘pharmacogenomics’ has been intro-
duced. While the latter term is broader and encompasses
all genes that may determine drug response [3] the distinc-
tion between the two terms is arbitrary and both are often
used interchangeably [4]. Not surprisingly, pharmacoge-
netic and pharmacogenomic discoveries are normally dis-
cussed in terms of their implementation into routine
healthcare prompting the possibility of genetic testing to
facilitate more effective drug therapy [5]. This has recently
been acknowledged by the regulatory authorities (such as
the US Food and Drug Administration, FDA and the
European Medicines Agency, EMEA) with drug label revi-
sions which include relevant pharmacogenetic informa-
tion and published guidance on the use of clinical
pharmacogenetics in early-phase clinical studies. Pharma-
cogenetics has therefore become one of the leading areas
of personalised medicine with a potential to change the
way in which healthcare is offered [6]. Despite its potential
importance in clinical practice, little is known about how
pharmacogenetics is portrayed in the news print media.* Correspondence: j.mcelnay@qub.ac.uk1Clinical and Practice Research Group, School of Pharmacy, Medical Biology
Centre, Queen’s University Belfast, 97 Lisburn Road, Belfast BT9 7BL, UK
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Recently, the analysis of media dialogue has been recog-
nised in the literature as an important aspect within the area
of health research [7]. Different media sources e.g. television,
radio, internet, magazines and newspapers all share in con-
veying information to the public and special interest groups
such as patients, healthcare professionals and policy makers
[8,9]. The mass media have also been used as an important
vehicle for communicating behavioural change to the public,
with varying degrees of success [10-12]. A recent survey
(Jan-Dec 2011) found that on average, 38.1% of adults in
Great Britain had read at least one national daily newspaper
within the previous day [13].
Stories about medicines in the media can be portrayed
negatively (harms of medicine), positively (improved efficacy
and safety) or may simply address recent findings and new
research. Newspaper articles can play an important role in
influencing demand for and provision of health services and
in changing health related behaviour [9,14]. They can also
create powerful changes in public opinion toward participa-
tion in research studies and policy discussions [7,15].
A number of studies which have investigated public and
patient opinions about the provision of pharmacogenetics
(PGx) testing have demonstrated support for the incorpor-
ation of PGx testing into patient management plans [16-19].
In recent years, the UK healthcare system has encouraged
patient involvement in the decision making process regard-
ing their healthcare [9]. Patient involvement in the decision
making process in the area of current interest, however,
implies that patients need to be properly informed about
potential use of PGx testing in their treatment plans. News-
print media play a key role in educating the public and shap-
ing their knowledge, and therefore has the potential to
influence opinion and attitudes toward such testing. As pa-
tients are becoming increasingly self-educated via the media
[20], it was deemed important to evaluate how the print
media portray information on PGx to the public. A number
of questions are particularly pertinent, for example, has
there been an increase in the number of newspaper articles
on PGx over the last decade? Were the articles equally dis-
tributed between the different types of newspapers and
hence broadly to the public? What potential benefits and
risks of PGx testing have been highlighted in the newspaper
stories and how were they framed to the public? In relation
to PGx testing, which group of disease(s) or drug(s) are
most commonly addressed by the print media?
The main aim of this study was therefore to explore,
through systematic content analysis, the nature and
trends in UK newspaper coverage of PGx in general
and the potential benefits and risks of PGx testing in
particular.
Methods
We performed content analysis of the coverage of PGx in
UK national newspapers published between 1st Jan 2001
until 31st Dec 2011. This timeframe was chosen to cover
the most recent decade of news articles in the field. An
overview of the methodological approach used in the
present study is presented in Figure 1:
Figure 1 Overview of the content analysis methodology adopted.
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Newspaper selection
The LexisNexis database [21] was used to obtain full text
reprints of published newspaper articles from electronic ar-
chives. A purposive sample of 10 UK national daily newspa-
pers and their Sunday equivalents was chosen. These
newspapers were selected since they had the highest circu-
lation figures at the time of initiating the study (May 2010)
according to the Audit Bureau of Circulations [22] and pro-
vided a broad spread, of both ‘broadsheet’ to ‘tabloid’ out-
lets. In addition, two newspapers that have a high volume
Sunday distribution (News of the World and The People)
were included. The timeframe selected was 1st Jan 2001
until 31st Dec 2011. The UK national newspapers included
in the study were as follows: The Sun, Daily Mail (The Mail
on Sunday), Daily Mirror (Sunday Mirror), Daily Star
(Sunday Star), Daily Telegraph (Sunday Telegraph), Express
(Sunday Express), Daily Record (Sunday Record), The Times
(Sunday Times), Financial Times, The Guardian (The Ob-
server), The News of the World and The People.
Search strategy and eligibility criteria
After empiric testing of different search terms, the
keyword adopted in the search strategy was “pharmaco-
gen!”. The “!” represented a wild card search and there-
fore the “pharmacogen!” search term encompassed
pharmacogenetic(s) and pharmacogenomic(s). Both broad
search terms were employed to minimise loss of relevant
articles.
We set criteria for the inclusion and exclusion of re-
trieved articles for detailed analysis. Initial inclusion cri-
teria included articles that contained any reference to
PGx (in humans), including articles in any format (e.g.
news article, editorial, letter to editor, etc...). Articles
were retrieved if the search term was captured in the
story headline, lead paragraph or body of the text. Re-
trieved articles were then subjected to more stringent
exclusion criteria which removed articles that empha-
sised another topic with only an indirect reference to
PGx (e.g. articles that contained only a brief mention of
PGx; <10% of the article), articles that dealt solely with
business issues (e.g. manufacturers’ share prices) or fo-
cused on PGx in the context of non-pharmacological
products (e.g. cosmetic or diet products). If the same
article appeared in both the daily and Sunday editions,
the duplicate was removed; in such cases, the article
with the higher word count was included in the analysis.
Data extraction and coding frame
A standardised coding frame was developed, taking into ac-
count the published literature and discussions within the re-
search team. To help ensure reliable coding, the coding
instrument included a series of topics with standardised cat-
egorical responses which consisted of three main sections:
a. Bibliographic information: the name of newspaper,
year of publication, positioning in the newspaper,
the length of the article and author name.
b. Article contents: assessment of benefit/advantages,
potential harm/risks, barriers to the application of
PGx, medicine/disease/gene related to PGx, source
of information and main commentator.
c. Judgment and rating: we recorded additional
variables including article slant “the skew of the
report written about the event” i.e. weighting of
benefits versus risks [23], article claim “Main
message conveyed to public” i.e. whether
exaggerated, balanced or understated when
compared with conventional knowledge on the
topic, and finally the quality of information [24].
The quality of information was assigned a subjective
rating on a scale of 1–10 and then classified as poor
(1–3), average/good (4–7) or excellent (8–10). An
example of a poor quality article may only have
contained a short statement about PGx or reported
inaccurate information on PGx testing, whereas an
article classified as high-quality would have in-
cluded, for example, definitive information about
PGx, have a scientific article as information source
or included information about barriers or facilitators
of PGx testing. In the case of newspaper articles
linked to a scientific journal publication, a fourth
section was applied to collect and compare the in-
formation presented in the two sources, in particu-
lar whether links with industry were cited and
whether conflicts of interests were disclosed.
Subjective rating of the main claim as exaggerated,
balanced or understated was made by an expert
coder trained in the field of PGx (BA) with
reference to scientific articles in the field. In the
case of indecision, other authors were consulted
and a consensus reached on rating of the article.
Data collection and coding of variables
Two independent researchers (pharmacists; BA, NG)
were employed in the coding process. In order to famil-
iarise the coders with the coding process, a pilot exer-
cise was conducted on a sample of the articles; n = 10).
Minor revisions were made post pilot as required after
discussion with the research team.
Having completed the pilot, one researcher (BA) coded
the entire set of relevant newspaper articles, while to
provide a quantitative estimate of overall reliability of the
coding process, a second researcher (NG) independently
assessed a random sample (21%) of the articles utilising a
web-based random number generator. The inter-coder
agreement on categorical variables was tested using Kappa
scores.
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Outcome measures and data analysis
Following data collection, all responses were coded and
entered into SPSS (version 18, SPSS Inc, USA). Descrip-
tive statistics (frequencies) were used to summarise the
data for the total sample. Differences in the reporting of
articles from different sources (tabloid versus broad-
sheet) and in the number of scientific articles published
compared with reports in newspaper articles were car-
ried out using a Chi square (χ2) test or Fisher Exact test
as appropriate. The Wilcoxon signed-rank test was used
to calculate the difference in the mean number of times
benefits and risks were mentioned. Spearman’s correl-
ation coefficient (Spearman’s rho r) was used to examine
the relationship between word counts and the number
of benefits and risks stated in the articles. The Mann–
Whitney U-test (non-parametric) was also used where
appropriate. Statistical significance was set at p ≤ 0.05.
Results
Inter-coder agreement
The rate of agreement between coders on dichotomous
variables was high e.g. whether benefits and risks were
mentioned in the article, however, when variables required
greater subjective judgement, such as claim and quality of
the information, lesser agreement was achieved. Kappa
scores across all coding variables ranged from 0.57 to 1,
indicating moderate to perfect agreement for all of the
candidate variables [25] (Table 1).
Frequency of reporting
A total of 256 articles mentioning PGx appeared in the
high circulation UK newspapers evaluated between Jan
2001- Dec 2011. Of the 256 articles captured by the
search terms, 26 duplicate articles were omitted, by
selecting the articles with the higher word counts. Of
the remaining 230 articles, 96 articles were retained after
applying the stricter exclusion criteria and thus were in-
cluded in the final detailed analysis, although the 230
articles were also included in a number of interim ana-
lyses, e.g. exploring the pattern of annual frequency of
reporting over time and differences in the reporting of
relevant articles in different newspaper types. This mini-
mised loss of relevant information pertaining to articles
excluded using the stricter inclusion/exclusion criteria
employed. A total of 11 articles were directly linked to
eight scientific journal papers. The mean word count for
the 96 articles was 590.5 words and 38 (40%) of these ar-
ticles appeared in the main news sections.
The pattern of the annual frequency of appearance of
articles distributed across the period was quite similar
whether for the 230 investigated articles or for the 96 ar-
ticles selected for detailed analysis (Figure 2). To allow
comparison with scientific publications over the period,
the frequency of articles included in PubMed® has also
been included in this figure. A breakdown of the articles
by newspaper showed that of the 230 articles, 216 (94%)
were published in daily newspapers, i.e. only 6% were
from Sunday newspapers. PGx articles occurred most
frequently in the Financial Times (32%), the Times
(25%) and the Guardian (13%). No articles about PGx
appeared in the Sunday Mirror, the Sunday Star, the
Sunday Record, the News of the World or the People
newspapers.
We found that many more articles pertaining to PGx
were published in the broadsheet newspapers compared
with the tabloid newspapers (85% vs 15% of the 96 arti-
cles; P < 0.001). However, over time, the number of arti-
cles published in the tabloids increased, i.e. 22% of the
articles were published in the second half of the investi-
gated period (July 2006–2011) compared to 7% in the
first half (2001- June 2006) (P = 0.04).
Content of the news stories selected for detailed
investigation
Within the 96 articles selected for detailed investigation,
the main themes covered were research (34%), medicines
Table 1 Inter-coder agreement on items within the coding frame
Question (number of choices) Observed agreement Kappa value
Main themes (8 choices) 90% 0.88
Key perspectives (7 choices) 90% 0.79
Benefit stated (yes/no) 100% 1.0
Risk stated (yes/no) 100% 1.0
Barrier stated (yes/no) 90% 0.79
Quotation stated (yes/no) 100% 1.0
Source of information (5 choices) 95% 0.91
Main voice (4 choices) 95% 0.89
Article slant (4 choices) 100% 1.0
Main claim (3 choices) 85% 0.58
Quality of information (3 choices) 80% 0.57
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(19%) and the biopharmaceutical industry (16%; Figure 3A).
Over half of the articles (55%) covered other themes in
addition to the main area of discussion. The key perspective
in the majority of articles was scientific (69%; Figure 3B).
Out of the 96 included articles, 95 (99%) stated at least
one benefit for the application of PGx. The total number
of benefits identified was 267 (range 1 to 7 per article).
Of those articles that qualified the potential benefit, 82
(86%) reported that using PGx based approaches/testing
would help to establish personalised medicine, 58 (61%)
reported improving drug efficacy and 50 (53%) reported
improving drug safety (Figure 4A). In contrast, only 33
articles (34%) mentioned at least one risk associated with
PGx application; the total number of risks highlighted was
50 (range 1 to 3 per article). Of those articles that detailed
potential risks, 17 (51%) reported that PGx would adversely
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Figure 2 Number of articles that mentioned PGx in the UK national newspapers studied superimposed with PubMed articles containing PGx as a key word.
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Figure 3 The distribution of PGx articles (n = 96) according to (A) the main themes covered and (B) the key perspectives addressed.
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affect the economic stability of the pharmaceutical industry,
11 articles (33%) reported a risk of discrimination being in-
troduced into medical treatment and 8 articles (24%) re-
ported the risk of loss of privacy and confidentiality of
genetic data (Figure 4B). Importantly, no article mentioned
a risk without listing at least one benefit. There was a signifi-
cant difference (p < 0.001) between the mean number of
times benefits (2.78) and risks (0.52) were stated in individ-
ual articles. There were significantly positive correlations be-
tween the length of the articles (word counts) and number
of benefits (Spearman’s rho r = 0.32, p = 0.001) and number
of risks (Spearman’s rho r = 0.331, p = 0.002) stated.
More than half of articles (57%; n = 55) reported potential
barriers to adopting PGx testing into routine practice. The
total number of barriers identified was 92 (the mean num-
ber of barriers was 0.96, range 1 to 5 per article). Of those
articles that qualified the nature of the barriers, 47% re-
ported commercial factors and 42% reported technology
factors (Figure 5).
Seventy five articles (78%) reported disease related PGx
items, 64 articles (67%) reported medicine related PGx items
and 37 (39%) of them reported gene related PGx items. Of
those articles that discussed disease related PGx topics, the
majority focused on chronic diseases such as cancer (mainly
breast cancer), cardiovascular diseases (CVD) and diseases
of the central nervous system (CNS). Medicine related PGx
topics focused mainly on, anticancer drugs whether licensed
such as Herceptin® (trastuzumab) or unlicensed at the time
of publication such as Iressa® (gefitinib), Tarceva®, (erlotinib)
or Velcade® (bortezomib). Furthermore, of those articles that
covered gene related PGx topics, the most common gene
discussed was the human epidural growth factor receptor 2
(HER2) gene followed by liver enzyme genes.
Over three quarters (77%; n = 74) of the articles cited the
source of information and in these scientists (73%) and sci-
entific journals (15%) were the main sources quoted. With
regards to the main voice, commentators from different dis-
ciplines (academic, scientific or industry spokesperson) were
the main voice for 60% (n = 58) of the articles while journal-
ists were the main voice for the remainder. The majority of
the articles (79%; n = 76) cited at least one expert and the
total number of commentators mentioned was 167. Eleven
scientific articles were referred to and in eight of these scien-
tific articles there was an acknowledgement of links with in-
dustry. Only one newspaper article mentioned the link with
industry.
Judgement of news stories
The majority of articles (66%; n = 63) were categorised as
having a positive slant, a third (33%; n = 32) were categorised
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Figure 4 Reported benefits (A) and risks (B) associated with PGx testing (n = 96 articles).
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as having a mixed slant and only one article was categorised
as having a neutral slant. The majority (66%; n = 63) of the
articles were categorised as having a balanced claim, 29% (n
= 28) were categorised as having an exaggerated claim and
5% (n = 5) of articles were categorised as having an under-
stated claim. More than half (59%; n = 57) of the articles
were categorised as having good information, a fifth (19%; n
= 18) were categorised as having excellent information and
22% (n = 21) were categorised as having poor information.
There was a significant positive correlation between the
overall size of the articles (word count) and the quality of
the information contained in the articles (Spearman’s rho r
= 0.62, p <0.001), i.e. longer articles tended to be of higher
quality.
Articles with the journalist as the main voice were
more likely to report the risk of PGx testing (p = 0.03)
and consequently demonstrated a less positive slant (p =
0.01). On the other hand, those articles with the journal-
ist as the main voice were less likely to include quota-
tions from experts (p < 0.001) and to use scientific
papers as sources of information (p < 0.001). A detailed
comparison of the articles with scientists and journalists
as the main voices is presented in Table 2.
Discussion
The medium of newspapers was selected in this study
for various reasons: firstly, newspapers are one of the
most popular UK media sources and have a wide range
of readership. Secondly, it was possible to easily access
and search published articles and address, for example,
how information was presented during specific periods
[23]. Thirdly, there is evidence that “newspaper cover-
age is strongly correlated with radio and television
reporting on similar issues” [23].
The results of this study revealed that PGx is a topic of
only marginal interest to UK newspaper editors as only
230 articles mentioned PGx over the 11 year period within
the higher readership newspapers included in the study.
Of 96 articles included in the detailed analysis, only 11 of
them (15%) were linked to scientific papers. Similarly, the
work of Bubela et al. [26] which involved a comparison of
genetic research covered in 26 newspapers from four
countries over a seven year period (Jan 1995- June 2001)
with scientific papers found only 2% (14 articles) from a
total of 626 articles had a PGx focus.
There was a marked unequal distribution of news-
paper articles addressing PGx in the broadsheet (85.4%)
vs tabloid (14.6%) press. A plausible explanation is that
editors of tabloid newspapers targeted less complex ma-
terial for their readership. This, however, has the poten-
tial to significantly impact the sections of the public that
are exposed to this type of material. In contrast, Hilton
and Hunt [27] reported that more articles about the
swine flu pandemic appeared in the tabloids than in the
‘serious’ and middle market UK newspapers.
Content of the news stories
In the current study, it was noted that the majority of ar-
ticles emphasised the benefits of PGx testing while pay-
ing less attention to potential risks, i.e. only 33 articles
(34%) mentioned the risks compared to 95 articles (99%)
that mentioned the benefits. Interestingly, beneficial ef-
fects (267 in total) were mentioned 5.3 times more fre-
quently than risks (50 in total). This trend of reporting
is consistent with other studies that reported media ana-
lyses on health topics. For example, Bubela and Caulfield
[26] in their comparison of newspaper articles and scientific
papers about genetic research reported that only 15% of
newspaper articles and an even smaller number of scientific
papers (5%) discussed risks. Similarly, Cassels et al. [28] re-
ported that 68% of Canadian newspaper articles did not
mention a single potential harm associated with five new
medications. Many researchers have commented on such
errors of exclusion [7,29,30]. Moynihan et al. [29] suggested
that journalists’ behaviour in reporting the positive effects
might reflect their enthusiasm to hype a certain topic, which
could be viewed as potentially misleading. Conversely, jour-
nalists have also been keen to hype harmful effects in certain
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Figure 5 Reported barriers to adoption of PGx testing (n = 96 articles).
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situations. For example, Bartlett et al. [31] reported that
newspapers were more likely to sensationlise and hype bad
news emanating from medical research when compared to
press releases. Also, Schwartz and Woloshin [32] reported
that most of news media coverage of mammography screen-
ing, and Tamoxifen for the prevention of breast cancer,
emphasised the risks.
It was noted in the present study that articles with the
journalist as the main voice were more likely to report risks
compared to those articles with the scientist as the main
voice. Reasons for this are unclear but could be due to jour-
nalists wishing to report both sides of the story i.e. risks and
benefits; whereas scientists tended not to consider the ad-
vances made by them as carrying any particular risks.
A high quality report should provide the reader with a
“balanced assessment” so that informed decisions can be
made [33,34]. If benefits are overstated, the public expect-
ation for cure or health improvement may be inflated and
unrealistically raised [3]. The opposite is also an issue i.e. if a
risk is overstated, this may generate unnecessary anxiety
which could impact adversely on patient behaviour [9].
There were significant positive correlations between the
size of articles (word count) and both the number of bene-
fits and risks stated in the articles. Consistent with this,
Holtzman et al. [29] identified that incompleteness of in-
formation presented in many of the articles published in
the US media about the discoveries related to genetic dis-
ease was partly due to the short length of the articles.
They found a significant positive correlation between the
length of article and its content score. This highlights the
importance of article length in comprehensively reporting
the significant issues on a particular topic.
In the present study, seven out of eight articles that cited
a scientific paper in which the researchers had links with
industry, failed to report that potential conflict of interest.
This finding is supported by work of Moynihan et al. [29]
and Bubela et al. [30] who found that the majority of
newspaper articles did not mention links with industry
(61%), and potential conflicts of interest (95%) respect-
ively, that had been detailed in published scientific papers.
Also, Holtzman et al. [35] found that only 5% of the 228
articles they researched mentioned potential conflict of
interest, although the majority of journalists thought it to
be an essential item in story reporting. These findings
highlight the fact that the media pay less attention to con-
flicts of interest disclosed, a factor that could easily lead to
misinterpretation of research findings [7,9,23]. Interest-
ingly, McComas and Simone [36], who conducted an ana-
lysis of media articles on conflict of interest in science
between 1992–2001, found that there was a steady trend
in the number of publications on conflict of interest over
the 10 year period, with a peak in 2000.
In the present study, the most frequently reported dis-
eases/medicines/genes that were related to PGx issues were
in the field of cancer. This finding highlights that advances
in the area of PGx are most notable in the oncology setting,
where Herceptin® and other anticancer drugs that can be
selected based on the patient genetic profile, are used [37].
Judgement of news stories
Of the 96 papers, 63 articles about PGx were presented to
the public with a positive slant (66%), no articles were
skewed negatively and 1 article (1%) was presented with a
neutral slant. The remainder of the articles were mixed, i.e.
referred to PGx as being both beneficial and harmful. This
is not surprising as the two variables used in determining
the category of slant were the reporting of benefits and
risks and in the majority of cases the benefits were empha-
sised and the risks were under-reported. In contrast,
Stebbing et al. [23] found that about 71% of news articles
Table 2 Comparison of articles with scientists and journalists as the main commentator
Variable Scientist main voice (n = 58) Journalist main voice (n = 38) P value
Mean number of words per article 605.8 567.1 NS
Benefit stated 58 (100%) 37 (97.4%) NS
Mean number of benefits stated 2.97 2.50 NS
Risk stated 15 (25.9%) 18 (47.4%) 0.03
Mean number of risks stated 0.38 0.74 0.03
Barrier stated 33 (56.9%) 22 (57.9%) NS
Mean number of barriers stated 0.91 1.0 NS
Articles with quotation from expert 53 (91.4%) 23 (60.5%) <0.001
Mean number of quotes per article 2.14 1.16 <0.001
Slant (positive) 44 (75.9%) 19 (50%) 0.01
Claim (exaggerated) 18 (31%) 10 (26.3%) NS
Quality of information (good) 34 (58.6%) 23 (60.5%) NS
Source of information (scientific papers) 10 (17.2%) 1 (2.6%) <0.001
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about patient safety were presented with a neutral slant. In
addition, 28 articles in this study (29%) were presented with
an exaggerated claim. Consistent with this, Bubela and
Caulfield [26] reported that a third of articles about genetic
research were categorised as having an exaggerated claim.
There are some limitations to the generalisability of the
present study findings since the analysis was limited to
higher circulation newspapers, however, circulation figures
can only be estimated based on the number of newspaper
sold and not on the actual readership. Additionally, the
newspaper database itself has limitations as complete
coverage of every article is not always achieved due to copy-
right restrictions [23]. Finally, newsprint media was the only
media surveyed in the present study; other mass media
news sources such as television, radio and the ‘web’ are also
important sources of health information to the public.
There is a strong correlation, however, between news items
covered by the range of mass media formats [38].
Conclusions
Newsprint coverage of public health issues, such as PGx
and personalised medicine, are an important vehicle in de-
livering health messages to the public and in changing per-
ceptions and behaviours. Journalists therefore have special
responsibilities in conveying accurate and unbiased infor-
mation about health and medicine, and should take into ac-
count that the reader might make important decisions
based on what is presented [28,30,39]. As suggested by
others [29] journalists should be more aware of advance-
ments in health and science and carefully consider the evi-
dence available, with particular attention to the following
points: (i) the type of benefit; (ii) the type of risk and costs;
(iii) groups of patients that can be helped and (iv) potential
conflict of interest. Such an approach has the potential to
improve the overall quality of media coverage. Scientists
also carry the responsibility in the first instance for making
important discoveries accessible to newspaper editors via
press releases and secondly in ensuring such press releases
are balanced in their claims.
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